What a boxed warning is

The short definition

The FDA’s own questions and answers on prescription labeling list the boxed warning ahead of section 1 of the full prescribing information. It holds contraindications or warnings about serious adverse reactions that may lead to death or serious injury. The text is bold and enclosed by a single black line, which is where the everyday name “black-box warning” comes from ^[3].

When a label has one, a shortened version also appears near the top of the Highlights page. The regulation limits that summary to 20 lines, requires a heading in capital letters that contains the word WARNING, and requires the line “See full prescribing information for complete boxed warning” straight after it ^[1].

When the FDA asks for a box

A 2011 FDA guidance on the warnings sections of labeling sets out when a boxed warning is ordinarily used ^[2]. In plain terms, there are three main situations:

• A reaction is so serious compared with the expected benefit, for example fatal, life-threatening or permanently disabling, that it has to be part of every benefit–risk decision ^[2].
• A serious reaction can be prevented, or made less frequent or less severe, by using the medicine carefully: choosing patients, monitoring them, or avoiding certain combinations or situations ^[2].
• The FDA approved the medicine only with restrictions on how it is distributed or used, because it can be used safely only under those conditions ^[2].
• Less often, a box highlights something else a prescriber especially needs to know, such as reduced effectiveness in a particular group of patients ^[2].

Observed risks, expected risks and animal data

The same guidance says boxed warnings are most often based on serious reactions that have actually been seen, but that a box can sometimes be based on a reaction that is anticipated. Its example is a class of medicines known to harm a developing baby, where every member may carry the box even if the effect has not been seen with that particular drug ^[2].

The regulation itself goes one step further. It says a box ordinarily has to rest on clinical data, but that serious toxicity in animals may be the basis when clinical data are missing ^[1]. That describes the GLP-1 labels well: their box warns about thyroid C-cell tumours that were seen in rodents, while stating that it is unknown whether this happens in humans ^[5].

Foundayo™ shows the anticipated-risk case most clearly. Orforglipron is not pharmacologically active in rats or mice, and a two-year rat study and a six-month transgenic mouse study found no tumours. The label still carries the box, because it does act on the human GLP-1 receptor and the rodent tumours are treated as an effect of that receptor class ^[13]. The thyroid warning article covers the risk itself.

One box, nine GLP-1 labels

Every GLP-1 label checked for this article opens with a box headed “Warning: risk of thyroid C-cell tumors”, and every box pairs the rodent finding with a contraindication for anyone who has had medullary thyroid carcinoma (MTC), whose close family has had it, or who has MEN 2. The wording of the animal finding is what differs, as the table shows.

None of these labels lists a change to its box under Recent Major Changes, where a substantive change to the box would have to appear for at least a year ^[1]. In other words, the box has not been recently rewritten on any of them, even though several other warnings changed in 2025 and 2026.

What goes inside, and where it leads

FDA guidance describes the box as a brief, concise summary of what the prescriber must consider, ideally in bullets or under subheadings so it is easy to scan ^[2]. The fuller discussion lives elsewhere in the label, usually in the Contraindications (section 4) or Warnings and Precautions (section 5) sections, and the regulation requires the box to point to it with the section number ^[1].

The Ozempic® label shows the pattern. Its box has a title, two short paragraphs and bracketed cross-references: section 5.1 for the warning, 13.1 for the animal studies and 4 for the contraindication ^[5]. Following those numbers is the quickest way to the evidence behind each sentence.

How the box echoes through the label

• Highlights: a condensed copy, no longer than 20 lines, sits near the top of page one ^[1].
• Recent Major Changes: a substantive change to the box is listed here with its month and year, and stays listed for at least a year ^[1][3].
• Medication Guide: the patient leaflet opens with a section on the most important information to know, and for GLP-1 medicines that section covers the same thyroid risk in everyday words, with the neck symptoms to report ^[5].
• Patient counselling (section 17): tells the prescriber to explain that the human relevance of the rodent finding is unknown, and to ask you to report possible thyroid tumour symptoms such as a neck lump, a hoarse voice, difficulty swallowing or breathlessness ^[5].

Europe and Canada handle the same risk differently

European product information has no boxed warning section. In the EU information for Wegovy®, the thyroid tumours appear under preclinical safety data, section 5.3, which calls them a class effect of GLP-1 receptor agonists and judges their relevance for humans to be low but not excludable; the only contraindication listed in section 4.3 is hypersensitivity ^[14]. The same document opens with a line saying the medicine is subject to additional monitoring, so that new safety information can be identified quickly ^[14]. That line is an EU monitoring status, not a boxed warning.

Canada has its own equivalent. The Canadian monograph for Mounjaro® puts the thyroid risk in section 3, titled “Serious Warnings and Precautions Box”, with the same contraindication. It adds that it is unknown whether monitoring with calcitonin blood tests or thyroid ultrasound would reduce the human risk ^[15].

What a boxed warning does not mean

A box is not a ban, and it is not a verdict that a medicine is unsafe. The FDA approves a use when it is supported by substantial evidence of effectiveness and the benefits outweigh the risks; the box marks the risks that deserve the most attention in that judgment ^[3].

It also does not tell you what to do on your own. The person who weighs a boxed risk against your situation is your prescriber, and questions about it, including whether to continue, belong in that conversation.

How prescribers actually use it

In 2024 the FDA’s drug center published a qualitative study in which 52 health care professionals were interviewed about boxed warnings in two different treatment settings. They described the box as one factor among several, alongside insurance coverage, which was mentioned most often, and the patient’s health, history and ability to keep taking the medicine ^[4].

Views varied with context. Clinicians with more experience of a condition found the box less useful, and opinions on whether a box overstated a risk differed between the two settings. The study concluded that boxes draw attention to serious risks as intended, but that their weight depends on the individual case. As an interview study, it describes views; it does not measure prescribing ^[4].

Turning the box into a conversation

If your medicine has a boxed warning, a useful step is to read it with the cross-referenced sections, write down what applies to your history, and bring those questions to your appointment. For the GLP-1 box, the history that matters is any personal or family history of MTC or MEN 2 ^[5].

Section 17 often tells the prescriber what to explain to you, so it is a fair place to start the conversation.

Ozempic®, Rybelsus®, Wegovy®, Victoza® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help